ALLUVI: A DEEP ANALYSIS INTO RETATRUTIDE’S PROMISE

Alluvi, formerly LY3414901, represents a significant advancement in obesity management. This twin -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist demonstrates remarkable efficacy in early clinical data, with impressive reduction in w